Are soccer players with dark skin tone more likely to receive red cards?

And why does this matter in drug development?

Statistical analytical methods are often taken for granted. In a recent crowdsourcing data analysis project, Nosek and co-workers found 29 research teams willing to analyze the same dataset [1]. The results varied from positive to neutral. How is this possible and what are the consequences? 

Read More

Topics: Clinical Trial Methods

Posted by Prof. Hans de Vries on Mar 12, 2019 5:11:00 PM

"Profil World" - The clinical diabetes research newsletter - February 2019

Dear all,

Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.

Read More

Topics: About Profil

Posted by Svenya Meister on Feb 27, 2019 5:24:00 PM

Artificial pancreas in type 2 diabetes

Close the loop in diabetes care

Artificial pancreas systems are medical products that use algorithms informed by continuous glucose monitoring (CGM) data of a given patient, thereby regulating the rates of a continuous subcutaneous insulin infusion through an insulin pump. In this way, artificial pancreas systems are taking over control of the patient’s blood glucose levels.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Feb 19, 2019 5:21:00 PM

Free webinar titled "Understanding the results of glucose clamp studies"

Profil continues the successful series of scientific webinars. On March 5th, 2019 we will air our webinar on "Understanding the results of glucose clamp studies". The session is presented by Dr. Tim Heise, Lead Scientist and Chairman of the Board of Directors at Profil. 

Read More

Topics: About Profil

Posted by Svenya Meister on Feb 5, 2019 5:12:00 PM

Digital Diabetes: better trials, better drugs, better care


Diabetes is a multidimensional challenge for global societies. Despite the availability of drugs and technology many patients don’t reach their treatment goals.  According to the UK National Diabetes Audit data 2016-2017 only 30% of people with type 1 diabetes and 67% of people with type 2 diabetes achieved a HbA1c target of 58 mmol/l (7.5%). When considering also blood pressure and cholesterol targets, these figures dropped to 19% and 41% respectively.

The good news is that diabetes leaves a huge room for Innovation. Risk factors are modifyable, type 2 diabetes is potentially reversible and the role of the patient’s self-management is of outstanding importance. Diabetes could serve as a paradigm for cracking down treatment inertia and narrowing the gap between the efficacy of investigational medicinal products seen in well controlled clinical trials and the lower than expected effectiveness of drugs observed in real-world chronic care (E2E gap) [1].

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Jan 29, 2019 5:13:00 PM

Glucose-Infusion-Rate based categorization of glucose clamps

The glucose clamp is a method for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of anti-diabetic drugs (e.g. insulin) where the blood glucose (BG) concentration lowering effect is antagonized by variable glucose infusion rates (GIR).

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Mareike Kuhlenkötter on Jan 15, 2019 5:03:00 PM

Update on Brexit: Impact on future and current clinical trials in Germany

As the withdrawal of the United Kingdom from the European Union is coming closer, the Competent Authority in Germany (BfArM) recently published their procedures for the period thereafter.

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Grit Andersen on Jan 8, 2019 5:05:00 PM

Happy new year 2019

2018 is over -  and the Profil blog has seen many interesting articles through the last months. We have posted about conferences, webinars and scientific topics for clinical diabetes researchers. 

We are happy to see that many readers are interested in our blog posts. Our most popular blogs deal with the error grid analysis, improvements of insulin injections and diabetic and hepatic encephalopathyWe are very pleased that the Profil blog has found so many readers again last year and we will continue to bring the most interesting topics to you also in 2019.

Read More

Topics: About Profil

Posted by Svenya Meister on Jan 3, 2019 5:23:00 PM

Pramlintide as adjunct therapy for the treatment of type 1 diabetes

Where are we today?

Insulin treatment for type 1 diabetes mellitus (T1D) has improved over the past decades due to advances in insulin formulations and administration techniques. Nevertheless, optimal glucose control and reaching HbA1c goals remain challenging for many patients. Consequently, the risk of subsequent micro- and macrovascular complications remains high and life expectancy is still reduced in this patient group so that there is an obvious need for improvement of current therapies or the development of new, additional treatments [1]. So what else can be done?


Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Susanne Famulla on Dec 19, 2018 5:12:00 PM

Obesity treatment with lorcaserin

New data on metabolic & cardiovascular safety and efficacy

Worldwide, the incidence of obesity is increasing dramatically having almost tripled in the last 40 years [1]. In 2016, 39% of adults aged 18 years and older were overweight - 13% were obese. Because obesity is associated with an array of metabolic pathologies, including cardiovascular disease, type 2 diabetes, musculoskeletal disorders, and even some cancers, identifying effective strategies for sustained weight loss are imperative.

Read More

Topics: Clinical trials in Obesity

Posted by Dr. Daniela Lamers on Dec 11, 2018 5:21:00 PM

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts